free viagra trial pack Provided by university of wisconsin, madison: primary outcome measures: this study will measure the tumor response rate of patients with gastrointestinal neuroendocrine tumors using response evaluation criteria in solid tumors (recist) criteria. [ time frame: every 8 weeks ] [ designated as safety issue: no ] secondary outcome measures: evaluate the toxicity an tolerability of panobinostat in the patient population [ time frame: on a daily basis ] [ designated as safety issue: yes ] evaluate the time to progression and the overall survival of patients with gastrointestinal neuroendocrine tumors treated with panobinostat [ time frame: on a daily basis ] [ designated as safety issue: no ] delineate the expression of notch 1 in neuroendocrine tumor samples before and during treatment with panobinostat [ time frame: prior to treatment and prior to cycle 3 of treatment ] [ designated as safety issue: no ] estimated enrollment: 33 study start date: may 2010 estimated study completion date: december 2012 estimated primary completion date: october 2012 (final data collection date for primary outcome measure) arms assigned interventions experimental: panobinostat this is a single arm trial. All patients will take panobinostat drug: panobinostat (lbh589) panobinostat will be taken once daily at 20 mg three times a week (every monday, wednesday, friday). It will be taken as long as patients are benefiting from treatment. eligibility ages eligible for study: 18 years and older genders eligible for study: both accepts healthy volunteers: no criteria inclusion criteria: histologically confirmed, metastatic, low grade neuroendocrine neoplasms. Small cell lung cancers, paragangliomas, and pheochromocytomas are excluded must have measurable disease as defined by recist 4 weeks from completion of major surgery, chemotherapy, or other systemic therapy or local liver therapy to study registration. Concurrent octreotide is allowed. Not allowed to be on concurrent chemotherapy or radiation 18 years of age or older ecog performance status of equal to or less than 2 able to sign and date a written informed consent prior to participation in the study baseline muga or echo must demonstrate lvef greater than or equal to the lower limit of the institutional normal must have the following laboratory criteria: neutrophil count greater than 1500/mm3, platelet count greater than 100,000/mm3l, hemoglobin greater than or equal to 9 g/dl, ast/sgot and alt/sgpt less than or equal to 2. 5 x uln, serum bilirubin less than or equal to 1. cheap online viagra discount generic viagra mg buy viagra cheap buy cheap viagra viagra for sale buy cheap viagra viagra without a doctor prescription cheap viagra online viagra without a doctor prescription cheap viagra online 5 x uln, serum creatinine less than or equal to 1. 5 x uln, total serum calcium greater than or equal to lln, serum potassium gre.